Bolt Biotherapeutics, Inc. — Q3 2021 Form 10-Q
Reporting period: Quarter and nine months ended September 30, 2021. Bolt is a clinical-stage immuno-oncology company; it has no product-sales revenue and remains focused on research and development. Figures below are in millions of dollars unless stated otherwise.
Financial results and liquidity
| Metric | Q3 2021 | Q3 2020 | Nine months 2021 | Nine months 2020 |
|---|---|---|---|---|
| Collaboration revenue | $0.752 | $0 | $0.752 | $0.231 |
| Research and development expense | $19.337 | $9.540 | $53.171 | $25.493 |
| General and administrative expense | $4.941 | $2.865 | $13.294 | $6.998 |
| Operating loss | $(23.526) | $(12.405) | $(65.713) | $(32.260) |
| Net loss | $(23.395) | $(10.001) | $(71.434) | $(29.693) |
| Basic and diluted loss per share | $(0.63) | $(4.73) | $(2.24) | $(14.19) |
Revenue is immaterial relative to operating expenses, so operating and net margins are not meaningful indicators of a commercial business at this stage. Net loss per share is affected by the IPO and resulting increase in weighted-average shares.
- At September 30, cash and cash equivalents were $23.6 million; short- and long-term investments totaled $266.9 million. Together, cash and investments were approximately $290.5 million. Current assets were $222.5 million and current liabilities were $23.7 million.
- Operating cash use was $39.3 million in the first nine months, versus $34.4 million in the prior-year period. Investing cash use was $253.2 million, largely reflecting purchases of marketable securities; financing provided $310.6 million, principally from the IPO, Series C-2 financing, and Genmab stock purchase.
- The company reported no outstanding debt. It had $24.9 million of operating lease liabilities, including current and non-current amounts; lease commitments extend over multiple years.
- Accumulated deficit was $179.8 million. The filing reports total liabilities of $58.6 million and stockholders’ equity of $274.9 million.
Material changes versus the prior comparable period
- Q3 R&D expense more than doubled year over year, rising $9.8 million; the nine-month increase was $27.7 million. The company attributed the increases mainly to manufacturing, personnel, facility, and clinical-trial costs.
- Q3 G&A expense increased $2.1 million year over year, and nine-month expense increased $6.3 million, primarily from higher personnel and professional-service costs.
- Net loss widened to $23.4 million for Q3 and $71.4 million for the nine-month period. The 2020 comparisons included non-cash gains from changes in fair value of preferred-stock purchase rights; the liability was settled and reclassified to equity in January 2021.
- The February 2021 IPO generated approximately $242.0 million in net proceeds. Preferred stock converted to common stock, and common shares outstanding were 37.25 million at September 30.
- Collaboration revenue for the nine months rose to $0.752 million from $0.231 million. The filing attributes 2021 revenue to Genmab services; the newly signed Innovent collaboration had not yet generated revenue by quarter-end.
Outlook, commentary, and risks
- Management said existing cash, cash equivalents, and marketable securities were expected to fund operations for at least the next 12 months. It cautioned that this estimate depends on assumptions and that clinical-development costs and timing are uncertain.
- The company expects significant expenses and operating losses to continue and R&D spending to increase as it advances clinical and preclinical programs. No product-sales revenue is expected unless and until a candidate is approved and commercialized.
- BDC-1001 was in the monotherapy dose-escalation portion of a Phase 1/2 trial. Management expected a monotherapy update in Q4 2021, to begin nivolumab combination dose escalation in Q4 2021, and to move into Phase 2 dose-expansion cohorts in 2022. BDC-2034 was anticipated to enter clinical development in 2022. These are forward-looking expectations, not assured outcomes.
- Genmab collaboration includes potential milestone payments of up to $285 million per qualifying candidate, plus royalties. Innovent collaboration includes potential option and development/sales milestone payments of up to $437.5 million and royalties for candidates developed and commercialized by Innovent. These contingent amounts are not current revenue or guaranteed proceeds.
- Risks include clinical and regulatory uncertainty, need for future capital, reliance on single-source suppliers and manufacturers, possible COVID-19-related disruption, and the uncertain scope and timing of the Toray research plan. The company disclosed up to $2.0 million in potential supply-agreement milestone payments and Stanford milestone and royalty obligations.
- Disclosure controls were deemed ineffective because of a material weakness in internal control over financial reporting, involving insufficient accounting personnel and inadequate formal accounting controls. Management described remediation steps, but the weakness was not yet considered remediated.
- No material change to previously disclosed risk factors was reported, and the company reported no material pending legal proceedings or off-balance-sheet arrangements.
Important facts for investors to verify
- Whether clinical-trial progress, including BDC-1001 monotherapy and the planned nivolumab combination, matches stated timelines and produces supportive data.
- Cash burn and investment balances in later filings, and whether management’s at-least-12-month funding estimate remains valid as development spending rises.
- Collaboration performance, contract-liability recognition, and whether contingent Genmab and Innovent options, milestones, or royalties become exercisable or payable.
- Progress in remediating the material weakness and whether controls are subsequently tested and reported as effective.
- Potential effects of supplier concentration, lease commitments, and the stated supply-agreement milestone obligations.